MiMedx Group, Inc. Accretion Expense
MiMedx Group, Inc. (MDXG) reported Accretion Expense of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-02-25
- MiMedx Group, Inc. accretion expense for fiscal 2025 was $200.00K.
| Period end | Accretion Expense 12 month |
|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B |